Answers are grounded in this paper and cite their sources.
• A group of 17 genes are differentially expressed between the different IKZF1 groups: IKZF1 plus , IKZF1 del and IKZF1 wild . • KCNA5, GREB1, PTPRB, SDK1 and EPOR , genes which encode cellular membrane markers, are associated with the presence of IKZF1 plus in BCP-ALL. • KCNA5 and GREB1 genes are the most promising biomarkers for predicting IKZF1 plus . • VPREB1 deletions are recurrent in the IKZF1 plus group of patients, being an extremely relevant biomarker to assist in therapeutic risk stratification for these patients. The presence of IKZF1 deletions has been associated with an increased relapse rate in B-cell precursor acute lymphoblastic leukaemia (BCP-ALL). There is a particular subset of IKZF1 del cases called IKZF1 plus (defined by the co-occurrence of IKZF1 del and deletions in CDKN2A / B, PAX5 , or the PAR1 region, in the absence of ERG deletions), which is also associated with worse prognosis, but some recent studies have not found major differences between the IKZF1 del and IKZF1 plus groups. Therefore, the IKZF1 plus group still needs further comprehension and our study aims to characterise the molecular heterogeneity and identify molecular markers exclusively associated with IKZF1 plus . Two independent series of cases (TARGET, n = 125 and GenLAb, n = 60) were evaluated by segregating patients into 3 groups: IKZF1 plus , IKZF1 del , and IKZF1 wild . Differential expression analyses showed that the membrane protein-coding genes most associated with the IKZF1 plus group were: KCNA5, GREB1, EPOR, SDK1 , and PTPRB . Notably, KCNA5 and GREB1 differential expression levels were validated in the GenLAb validation series. Regarding copy number alterations, we observed a high frequency of VPREB1 deletions in the IKZF1 plus group, as well as additional exclusive deletions in the CD200 and BTLA genes. Recent research suggests that the importance of the IKZF1 plus profile varies depending on the genetic subgroup. In this scenario, we found associations between IKZF1 plus and certain genes in BCP-ALL, being KCNA5 and GREB1 the most promising biomarkers for predicting IKZF1 plus . A deeper understanding of these genetic profiles will allow a better risk assessment and offer precise rationale for therapeutic strategies in BCP-ALL.
No takes yet. Share an insight, caveat, or question.
Blunck et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: